A study conducted by NYU researchers has identified a distinct "microbial signature" in children recently diagnosed with Crohn's disease.
This signature, characterized by an increased presence of pro-inflammatory bacteria and a reduction in protective bacteria, differentiates Crohn's patients from children with other gastrointestinal conditions, such as irritable bowel syndrome.
Research Findings
Published in the journal Physiological Reports, the study analyzed fecal samples from 43 children with Crohn's disease and 139 with functional gastrointestinal issues. Key observations include:
- Children with Crohn's exhibited lower microbial diversity in their guts.
- Their microbiomes contained higher levels of pro-inflammatory bacteria (e.g., Fusobacteria, Proteobacteria) and lower levels of beneficial bacteria (e.g., Firmicutes, Verrucomicrobia).
- Disease severity correlated with even less microbial diversity and specific bacterial patterns, including higher levels of pro-inflammatory Hungatella and Veillonella, and lower levels of protective Lachnospiraceae.
Implications for Diagnosis and Treatment
These findings suggest that fecal microbiome profiling could serve as an additional tool for diagnosing and managing Crohn's disease, potentially distinguishing it from other gastrointestinal disorders.
Study author Ryan Zanganeh noted that this approach could aid in understanding disease progression, identifying microbial biomarkers, and predicting treatment response, leading to more personalized care for pediatric Crohn's disease.
Future research aims to investigate the connections between the gut and oral microbiomes, as well as the influence of environmental factors and synthetic chemicals on the microbiome in relation to Crohn's disease. The overarching goal is to develop microbiome-targeted treatments, such as therapeutic probiotics or specific antimicrobial therapies, to rebalance gut bacteria and reduce inflammation.